| __timestamp | Axsome Therapeutics, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 5496000 |
| Thursday, January 1, 2015 | 2419289 | 9786000 |
| Friday, January 1, 2016 | 6343648 | 6792000 |
| Sunday, January 1, 2017 | 7206691 | 7313000 |
| Monday, January 1, 2018 | 9351522 | 8382000 |
| Tuesday, January 1, 2019 | 13598030 | 10803000 |
| Wednesday, January 1, 2020 | 28896749 | 12944000 |
| Friday, January 1, 2021 | 66646205 | 21967000 |
| Saturday, January 1, 2022 | 159253661 | 32810000 |
| Sunday, January 1, 2023 | 323123000 | 46542000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. Over the past decade, Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Axsome's SG&A expenses skyrocketed by over 23,000%, reflecting its aggressive growth strategy. In contrast, Xenon's expenses increased by approximately 750%, indicating a more conservative approach. By 2023, Axsome's SG&A expenses were nearly seven times higher than Xenon's, highlighting its significant investment in operational expansion. This divergence in spending underscores the varied strategies within the biotech sector, where companies balance between rapid growth and sustainable development. As the industry evolves, these financial insights offer a glimpse into the strategic priorities shaping the future of biotech innovation.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
GSK plc and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Genmab A/S vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Ligand Pharmaceuticals Incorporated